Back To Her Biotech Roots: An Interview With Anna Protopapas

After almost two decades at Millennium/Takeda, Anna Protopapas moves to tiny Mersana Therapeutics, which aims to power up oncology with its Fleximer drug conjugate platform.

More from Strategy

More from Business